In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors

被引：0
|
作者：
Geretti, E.
Espelin, C.
Adiwijaya, B.
Coma, S.
Koncki, Z.
Sumner, P.
Dumont, N.
Garcia, G.
Bloom, T.
Janovsky, J.
Reynolds, J.
Campbell, K.
Moyo, V.
Molnar, I.
LoRusso, P.
Krop, I.
Miller, K.
Ma, C.
Munster, P.
Wickham, T.
机构：
[1] Merrimack Pharmaceut Inc, Cambridge, MA USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-21-40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-21-40
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors
    Geretti, E.
    Espelin, C.
    Adiwijaya, B.
    Dumont, N.
    Coma, S.
    Koncki, Z.
    Garcia, G.
    Bloom, T.
    Rimkunas, V.
    Reynolds, J.
    Campbell, K.
    Moyo, V.
    Molnar, I.
    Lorusso, P.
    Miller, K.
    Ma, C.
    Krop, I. E.
    Munster, P.
    Wickham, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo
    Geretti, Elena
    Espelin, Christopher
    Adiwijaya, Bambang
    Dumont, Nancy
    Coma, Silvia
    Koncki, Zachary
    Minh Pham
    Garcia, Gabriela
    Bloom, Troy
    Rimkunas, Victoria
    Reynolds, Joe
    Campbell, Karen
    Moyo, Victor
    Molnar, Istvan
    LoRusso, Patricia
    Krop, Ian
    Miller, Kathy
    Ma, Cynthia
    Munster, Pamela
    Wickham, Thomas
    CANCER RESEARCH, 2016, 76
  • [3] MM-302, HER2-targeted liposomal doxorubicin, does not impair cardiomyocyte function in vitro
    Reynolds, Joseph
    Klinz, Stephan
    Leonard, Shannon
    Geretti, Elena
    Lee, Helen
    Eckelhofer, Isabelle
    Gaddy, Daniel
    Hendriks, Bart
    Wickham, Tom
    CANCER RESEARCH, 2011, 71
  • [4] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
    Munster, Pamela
    Krop, Ian E.
    LoRusso, Patricia
    Ma, Cynthia
    Siegel, Barry A.
    Shields, Anthony F.
    Molnar, Istvan
    Wickham, Thomas J.
    Reynolds, Joseph
    Campbell, Karen
    Hendriks, Bart S.
    Adiwijaya, Bambang S.
    Geretti, Elena
    Moyo, Victor
    Miller, Kathy D.
    BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1086 - 1093
  • [5] Receptor-mediated binding of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 increases liposome binding, nuclear doxorubicin, DNA damage and efficacy relative to untargeted PEGylated liposomal doxorubicin (PLD/Doxil)
    Espelin, C.
    Geretti, E.
    Coma, S.
    Koncki, Z.
    Leonard, S.
    Dumont, N.
    Reynolds, J.
    Molnar, I.
    Wickham, T.
    CANCER RESEARCH, 2017, 77
  • [6] OPTIMIZING DELIVERY OF HER2-TARGETED LIPOSOMAL DOXORUBICIN (MM-302) THROUGH IMAGING, COMPUTATIONAL ANALYSES AND EXPERIMENTATION
    Hendriks, Bart
    DRUG METABOLISM REVIEWS, 2014, 45 : 16 - 16
  • [7] A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+metastatic breast cancer
    LoRusso, Patricia
    Krop, Ian
    Miller, Kathy
    Ma, Cynthia
    Siegel, Barry A.
    Shields, Anthony F.
    Molnar, Istvan
    Wickham, Thomas
    Reynolds, Joseph
    Campbell, Karen
    Hendriks, Bart
    McClure, Ty
    Moyo, Victor
    Munster, Pamela
    CANCER RESEARCH, 2015, 75
  • [8] A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-Positive Breast Cancer
    Wickham, T.
    Futch, K.
    CANCER RESEARCH, 2012, 72
  • [9] A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer
    Munster, Pamela N.
    Miller, Kathy
    Krop, Ian E.
    Dhindsa, Navreet
    Reynolds, Joe
    Geretti, Elena
    Niyikiza, Clet
    Nielsen, Ulrik
    Hendriks, Bart
    Wickham, Thomas J.
    Moyo, Victor M.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
    Geretti, Elena
    Leonard, Shannon Curtis
    Dumont, Nancy
    Lee, Helen
    Zheng, Jinzi
    De Souza, Raquel
    Gaddy, Daniel F.
    Espelin, Christopher W.
    Jaffray, David A.
    Moyo, Victor
    Nielsen, Ulrik B.
    Wickham, Thomas J.
    Hendriks, Bart S.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (09) : 2060 - 2071
12345